Repository logo
 
Publication

Portuguese in vitro antibiotic susceptibilities favor current nontuberculous mycobacteria treatment guidelines

2018-10-08Journal article Restricted access
Simple item page
dc.contributor.authorDurão, Vera
dc.contributor.authorSilva, Anabela
dc.contributor.authorMacedo, Rita
dc.contributor.authorDurão, Paulo
dc.contributor.authorSantos-Silva, André
dc.contributor.authorDuarte, Raquel
dc.date.accessioned2019-03-21T16:14:19Z
dc.date.available2022-12-01T01:30:22Z
dc.date.issued2018-10-08
dc.descriptionSupplementary material associated with this article can be found in the online version available at doi:10.1016/j.pulmoe.2018.09.001.pt_PT
dc.description.abstractSetting: Nontuberculous mycobacteria (NTM) are increasingly recognized as causative agents of opportunistic infections in humans for which effective treatment is challenging. There is, however, very little information on the prevalence of NTM drug resistance in Portugal. Objective and Design: Our aim was to analyze the drug susceptibility testing (DST) performed in NTM at the Portuguese National Health Institute Dr. Ricardo Jorge from February 2003 to February 2016. A total of 262 DST were included in the analysis. Results: Most (94%) M. avium intracellulare complex isolates showed in vitro susceptibility to clarithromycin. All M. kansasii isolates were susceptible to rifampicin and ethambutol and 97.1% were susceptible to isoniazid. The majority of rapidly-growing mycobacteria (RGM) demonstrated in vitro susceptibility to amikacin, clarithromycin and cefoxitin. However, in RGM there was a marked increase on the relative risk of having sulfamethoxazole resistance in isolates resistant to ciprofloxacin compared to susceptible isolates. Conclusion: Tested NTM in Portugal revealed in vitro susceptibility to most of the antimicrobials currently recommended for treatment. However, our results also suggest that sulfamethoxazole should be avoided in treatment of RGM resistant to ciprofloxacin (or vice versa). Further trials that correlate the in vitro DST results with the clinical outcome are needed in order to reach conclusions on efficient antimicrobial therapy.pt_PT
dc.description.versioninfo:eu-repo/semantics/publishedVersionpt_PT
dc.identifier.citationPulmonology. 2018 Oct 8. pii: S2531-0437(18)30129-6. doi: 10.1016/j.pulmoe.2018.09.001. [Epub ahead of print]pt_PT
dc.identifier.doi10.1016/j.pulmoe.2018.09.001pt_PT
dc.identifier.issn2531-0429
dc.identifier.urihttp://hdl.handle.net/10400.18/6271
dc.language.isoengpt_PT
dc.peerreviewedyespt_PT
dc.publisherElsevier/ Sociedade Portuguesa de Pneumologiapt_PT
dc.relation.publisherversionhttps://www.sciencedirect.com/science/article/pii/S2531043718301296?via%3Dihubpt_PT
dc.subjectAntibiotic Resistancept_PT
dc.subjectAntimicrobial Treatmentpt_PT
dc.subjectDrug Susceptibility Testingpt_PT
dc.subjectNontuberculous mycobacteriapt_PT
dc.subjectInfecções Gastrointestinais
dc.titlePortuguese in vitro antibiotic susceptibilities favor current nontuberculous mycobacteria treatment guidelinespt_PT
dc.typejournal article
dspace.entity.typePublication
oaire.citation.titlePulmonologypt_PT
rcaap.rightsopenAccesspt_PT
rcaap.typearticlept_PT

Files

Original bundle
Now showing 1 - 1 of 1
No Thumbnail Available
Name:
Portuguese in vitro antibiotic susceptibilities.pdf
Size:
448.6 KB
Format:
Adobe Portable Document Format
Download
License bundle
Now showing 1 - 1 of 1
No Thumbnail Available
Name:
license.txt
Size:
1.71 KB
Format:
Item-specific license agreed upon to submission
Description:
Download

Collections

DDI - Artigos em revistas nacionais